Skip to main content

Table 1 Overview of all cases analyzed and entity specific alterations with frequencies

From: A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology

Entity # Aberrations # Frequency
Astrocytic glioma, IDH-mutant (WHO grade II/III/IV) 19 IDH1/2 19 100%
TP53 18 95%
ATRX 7 37%
CDKN2A HomDel 2 11%
Oligodendroglioma, IDH-mutant 1p/19q-codeleted
(WHO grade II/III)
14 IDH1/2 14 100%
1p/19q LOH 14 100%
TERTp 14 100%
CIC 11 79%
FUBP1 4 29%
Astrocytic glioma, IDH-wildtype (WHO grade I/II/III/IV) 42 TERTp 30 71%
10 DEL / 7 AMP 14 33%
EGFR Highcopy 9 21%
TP53 9 21%
NF1 5 12%
BRAF 4 10%
Diffuse midline glioma, H3K27M-mutant (WHO grade IV) 2 H3F3A 2 100%
TP53 2 100%
Meningioma (WHO grade I/II/III) 19 NF2 15 79%
SMARCB1 15 79%
1p DEL 12 63%
CDKN2A HomDel 4 21%
TERTp 0 0%
Medulloblastoma (WHO grade IV) 8 TERTp 3 38%
TP53 2 25%
OTX2 Highcopy 1 13%
CTNNB1 1 13%
Monosomy 6 1 13%
Isochromosome 17 1 13%
  1. AMP: amplification, DEL: deletion, Highcopy: highcopy amplification, HomDel: homozygous loss, LOH: loss of heterozygosity